+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma



Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma



Leukemia and Lymphoma 49(11): 2091-2098



Early treatment failure is still a clinical challenge despite high cure rates in Hodgkin lymphoma (HL) patients. To identify the biological risk factors predicting early treatment failure, we performed a retrospective case-control study. Forty-seven pretherapeutic serum samples were available from 47 advanced stage HL patients with early treatment failure and from 47 matched controls in complete remission. All patients were treated within German Hodgkin Study Group phase 3 trials. Matching was done according to treatment, stage, age, gender, International Prognostic Score (IPS) and histological subtype. Pretreatment serum levels of 30 cytokines, chemokines and soluble receptors were determined using immunoassays and flow cytometer based cytometric bead arrays. Only interleukin-10 serum levels were significantly associated with early treatment failure after statistical correction for multitesting (paired-sign test, p = 0.0008). In summary, pretherapeutic interleukin-10 levels are associated with early treatment failure within 12 months after the end of treatment in advanced stage HL independently from known clinical factors such as age or IPS.

(PDF emailed within 0-6 h: $19.90)

Accession: 052935295

Download citation: RISBibTeXText

PMID: 19021051

DOI: 10.1080/10428190802441339


Related references

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Annals of Oncology 11(5): 617-623, 2000

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leukemia and Lymphoma 53(5): 812-819, 2012

Tailored BEACOPP regimen for standard and high risk Hodgkin lymphoma based on early response to Ga67 scintigraphy and the international prognostic score for advanced Hodgkin disease. Blood 98(11 Part 2): 240b, November 16, 2001

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. Journal of Clinical Oncology 2019: Jco1801799, 2019

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. Journal of Clinical Oncology 30(27): 3383-3388, 2012

The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma. British Journal of Haematology 2018, 2018

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95(12): 2534-2538, 2002

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology 25(24): 3746-3752, 2007

Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. Leukemia and Lymphoma 50(10): 1718-1720, 2010

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7(44): 72219-72228, 2016

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Annals of Oncology 13(12): 1908-1914, 2002

Tailoring chemotherapy regimen for standard and high risk Hodgkin lymphoma based on early response to Ga67/F18 DG scintigraphy and international prognostic score for advanced disease A report of 76 patients treated in single institution. Blood 102(11): 638a, November 16, 2003

Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 86(3): 274-281, 2001

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. British Journal of Haematology 171(4): 530-538, 2016

Tailored BEACOPP Regimen for Unfavorable Hodgkin Lymphoma Based on Early Response to Ga67 /F18dg Scintigraphy and International Prognostic Score for Advanced Disease. Blood 100(11): Abstract No 3081, November 16, 2002